ChemoCentryx (NASDAQ:CCXI) Trading 7.7% Higher

Shares of ChemoCentryx, Inc. (NASDAQ:CCXIGet Rating) traded up 7.7% during mid-day trading on Friday . The stock traded as high as $25.91 and last traded at $25.73. 15,244 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,156,330 shares. The stock had previously closed at $23.89.

Several equities research analysts recently issued reports on the stock. assumed coverage on shares of ChemoCentryx in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Stifel Nicolaus restated a “buy” rating and issued a $85.00 target price on shares of ChemoCentryx in a report on Friday, March 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to, the company currently has a consensus rating of “Buy” and a consensus price target of $73.43.

The company’s 50 day moving average price is $21.06 and its two-hundred day moving average price is $26.83. The firm has a market cap of $1.85 billion, a PE ratio of -11.89 and a beta of 1.95. The company has a current ratio of 5.11, a quick ratio of 5.07 and a debt-to-equity ratio of 0.02.

ChemoCentryx (NASDAQ:CCXIGet Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). ChemoCentryx had a negative net margin of 514.64% and a negative return on equity of 47.24%. The firm had revenue of $5.46 million for the quarter, compared to analysts’ expectations of $4.43 million. During the same quarter last year, the firm posted ($0.43) EPS. Equities research analysts expect that ChemoCentryx, Inc. will post -1.93 earnings per share for the current fiscal year.

In related news, Director James L. Tyree sold 3,863 shares of ChemoCentryx stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $25.66, for a total transaction of $99,124.58. Following the transaction, the director now owns 19,138 shares in the company, valued at approximately $491,081.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 8.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Total Clarity Wealth Management Inc. bought a new stake in ChemoCentryx in the 4th quarter valued at $29,000. CWM LLC bought a new stake in ChemoCentryx in the 4th quarter valued at $37,000. UMB Bank N A MO bought a new stake in ChemoCentryx in the 4th quarter valued at $37,000. Paragon Capital Management Ltd bought a new stake in ChemoCentryx in the 4th quarter valued at $42,000. Finally, Prospera Financial Services Inc bought a new stake in ChemoCentryx in the 1st quarter valued at $46,000. Institutional investors own 82.28% of the company’s stock.

ChemoCentryx Company Profile (NASDAQ:CCXI)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with's FREE daily email newsletter.